Inclusion Criteria:

        1. Age ≥162. B-ALL: high risk or relapsed histologically confirmed CD19+ B-ALL following
        standard therapy requiring salvage in whom alternative therapies are deemed inappropriate
        by their treating physician Or DLBCL: relapsed/refractory DLBCL (incl. transformed FL but
        not Richter's transformation) following ≥2 prior lines of therapy including Rituximab and
        anthracycline Or CLL/SLL: relapsed/refractory CLL/SLL following ≥2 prior lines of therapy
        including Ibrutinib or other Bruton's Tyrosine Kinase (BTK) inhibitors Or Indolent B-NHL
        (either Follicular Lymphoma, Mantle Cell Lymphoma or Marginal Zone Lymhpoma) which is
        relapsed / refractory following ≥2 prior lines of therapy including Ritux-imab and
        anthracycline 3. Agreement to have a pregnancy test, use adequate contraception (if
        applicable) 4.Written informed consent

        Exclusion criteria for registration:

          1. CD19 negative disease

          2. B-ALL and CLL: overt CNS involvement (i.e.: patients with CNS2 with neurological
             symp-toms or patients with CNS3; appendix 2)

          3. B-NHL and CLL/SLL: primary or secondary CNS lymphoma

          4. Isolated extramedullary disease (B-ALL and CLL)

          5. Active hepatitis B, C or HIV infection

          6. Oxygen saturation ≤ 90% on air

          7. Bilirubin >2 x upper limit of normal

          8. GFR <50ml/min

          9. Women who are pregnant or breast feeding

         10. Stem Cell Transplant patients only: active significant acute GVHD (overall Grade ≥ II,
             Se-attle criteria) or moderate/severe chronic GVHD (NIH consensus criteria) requiring
             im-munosuppressive therapy and/or systemic steroids (see appendix 5)

         11. Inability to tolerate leucapheresis

         12. Karnofsky score <60% (see appendix 3)

         13. Patients who have experienced significant neurotoxicity following blinatumomab

         14. Known allergy to albumin or DMSO

         15. Life expectancy <3months

         16. Arrhythmias or significant cardiac disease and left ventricular ejection fraction <40%

         17. Pre-existing neurological disorders (other than CNS involvement of underlying
             haemato-logical malignancy)

         18. DLBCL only:

               -  Any contraindications to PD-1 antibody Pembrolizumab

               -  History of autoimmune disease (e.g. Crohn's, rheumatoid arthritis, systemic
                  lupus) re-sulting in end organ injury or requiring systemic
                  immunosuppression/systemic disease modifying agents within the last 24 months

               -  Evidence of active pneumonitis on chest computed tomography (CT) scan at
                  screening or history of drug-induced pneumonitis, idiopathic pulmonary fibrosis,
                  organising pneu-monia (e.g. bronchiolitis obliterans), or idiopathic pneumonitis.
                  Prior radiation pneu-monitis in the radiation field (fibrosis) is allowed (if >24
                  weeks since the event)

               -  Prior limited radiation therapy (e.g. radiation to bone metastasis for pain
                  control) within 4 weeks of CAR T-cell infusion or chest/mediastinal radiation
                  within 24 weeks of CAR T-cellinfusion

        Exclusion criteria: for CD19CAR T-cell infusion at Day 0 (all patients):

          1. Severe intercurrent infection at the time of scheduled CD19CAR T-cell infusion

          2. Requirement for supplementary oxygen or active pulmonary infiltrates at the time of
             scheduled CD19CAR T-cell infusion

          3. Allogeneic transplant recipients with active significant acute GVHD overall grade ≥II
             or moderate/severe chronic GVHD requiring systemic steroids or other
             immunosuppres-sion at the time of scheduled CD19CAR T-cell infusion. Note: Such
             patients will be ex-cluded until the patient is GVHD free and off steroids

        Exclusion criteria: for supplementary CD19CAR T-cell infusion Day 9 (B-ALL and CLL/SLL
        pa-tients):

          1. Severe intercurrent infection at the time of scheduled CD19CAR T-cell infusion

          2. Requirement for supplementary oxygen or active pulmonary infiltrates at the time of
             sched-uled CD19CAR T-cell infusion

          3. Grade 3-4 CRS and or grade 3-4 neurotoxicity following Day 0 CD19CAR T-cell dose

          4. Grade 1-2 neurotoxicity (if occurred) following Day 0 CD19CAR T-cell dose that has not
             fully resolved prior to proposed administration of 2nd CD19CAR T-cell dose

          5. Persisting Grade 2 CRS following Day 0 CD19CAR T-cell dose that has not resolved to ≤
             Grade 1 CRS prior to proposed administration of 2nd CD19CAR T-cell dose

          6. Allogeneic transplant recipients with active significant acute GVHD overall grade ≥II
             or moderate/severe chronic GVHD requiring systemic steroids or other immunosuppression
             at the time of scheduled CD19CAR T-cell infusion* *Note: Such patients will be
             excluded until the patient is GVHD free and off steroids